Oliver Luxxe Assets LLC Invests $1.82 Million in ANI Pharmaceuticals, Inc. $ANIP

Oliver Luxxe Assets LLC purchased a new position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 23,098 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,823,000. Oliver Luxxe Assets LLC owned about 0.10% of ANI Pharmaceuticals as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Arrowstreet Capital Limited Partnership bought a new stake in ANI Pharmaceuticals in the third quarter worth $32,992,000. Balyasny Asset Management L.P. increased its holdings in shares of ANI Pharmaceuticals by 2,785.7% during the third quarter. Balyasny Asset Management L.P. now owns 286,149 shares of the specialty pharmaceutical company’s stock valued at $26,211,000 after acquiring an additional 276,233 shares in the last quarter. Divisadero Street Capital Management LP purchased a new position in shares of ANI Pharmaceuticals in the 3rd quarter worth about $21,454,000. Rubric Capital Management LP raised its position in shares of ANI Pharmaceuticals by 354.7% in the 2nd quarter. Rubric Capital Management LP now owns 257,669 shares of the specialty pharmaceutical company’s stock worth $16,813,000 after purchasing an additional 200,998 shares during the last quarter. Finally, UBS Group AG boosted its stake in ANI Pharmaceuticals by 45.8% in the 3rd quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock worth $54,032,000 after purchasing an additional 185,172 shares in the last quarter. Institutional investors own 76.05% of the company’s stock.

Insider Transactions at ANI Pharmaceuticals

In related news, insider Christopher Mutz sold 5,323 shares of the stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $78.02, for a total transaction of $415,300.46. Following the completion of the sale, the insider owned 84,840 shares in the company, valued at approximately $6,619,216.80. This trade represents a 5.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Krista Davis sold 2,084 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $77.53, for a total value of $161,572.52. Following the completion of the transaction, the senior vice president directly owned 50,993 shares in the company, valued at approximately $3,953,487.29. This represents a 3.93% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 27,860 shares of company stock valued at $2,114,771. 11.10% of the stock is owned by corporate insiders.

ANI Pharmaceuticals Trading Down 0.2%

Shares of ANI Pharmaceuticals stock opened at $74.67 on Friday. ANI Pharmaceuticals, Inc. has a fifty-two week low of $56.71 and a fifty-two week high of $99.50. The company has a debt-to-equity ratio of 1.11, a quick ratio of 2.19 and a current ratio of 2.71. The company has a market capitalization of $1.68 billion, a P/E ratio of 22.22 and a beta of 0.52. The company has a fifty day moving average of $78.66 and a 200 day moving average of $84.64.

Wall Street Analysts Forecast Growth

ANIP has been the topic of several recent analyst reports. Weiss Ratings reissued a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research report on Monday, December 29th. Wall Street Zen cut ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, March 14th. Zacks Research lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 6th. Barclays began coverage on shares of ANI Pharmaceuticals in a report on Tuesday, December 9th. They set an “overweight” rating and a $100.00 target price for the company. Finally, Guggenheim boosted their price objective on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a “buy” rating in a research report on Friday, January 16th. Five research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, ANI Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $107.33.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.